Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-03-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于获得创新药HSK40118片《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a clinical trial approval notice for a new innovative drug (HSK40118) from the National Medical Products Administration. It details the drug's development background, clinical trial approval, and associated risks. The document is short (1355 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement of regulatory approval related to drug development, not a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a clinical trial approval, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-15 Chinese
关于创新药HSK31679片II期临床试验获得伦理批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving ethical approval for a Phase II clinical trial of a new drug. It contains no financial data, no regulatory filings related to financial performance, no management or board changes, no voting results, and no report publication statements. The content is focused on clinical trial progress and risk warnings related to the drug development process. This type of announcement does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is also not a regulatory filing related to financial compliance. Given the nature of the announcement and its focus on clinical trial progress, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-03-14 Chinese
关于控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a controlling shareholder of the company. It details the number of shares released from pledge, the proportion of shares involved, and cumulative pledge status. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about share pledge status, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is an announcement rather than a report.
2023-03-10 Chinese
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the proportion of shares involved, pledge start and end dates, and the pledgee. There is no financial data, no discussion of financial results, no management commentary, and no mention of meetings or votes. The document is a regulatory announcement about share pledging, which is a capital-related event but specifically about share pledges by a major shareholder. This fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Share Issue/Capital Change (SHA) or Major Shareholding Notification (MRQ). The document length is short and it is not a report or a presentation. Therefore, the classification is RNS with high confidence.
2023-03-08 Chinese
第四届董事会第四十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 海思科医药集团股份有限公司, detailing the approval of a proposal regarding the acquisition of subsidiary equity. It includes voting results and mentions the board meeting date and participants. The content focuses on board decisions and changes related to company structure and ownership. The document length is short (850 characters), and it is not a full financial report or earnings release. It is not an announcement of voting results at a shareholder meeting but a board resolution announcement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management decisions, including significant corporate actions approved by the board.
2023-03-03 Chinese
关于收购控股子公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 100% equity stakes in two subsidiaries by a holding company. It includes transaction overview, parties involved, financial data of the targets, valuation methods and results, transaction terms, and impact on the company. It is not a full financial report but a specific corporate transaction announcement. The document is lengthy and detailed, focusing on a capital transaction involving share acquisition and valuation. It does not contain quarterly or annual financial statements or earnings highlights, nor is it a regulatory certification or voting result. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions of subsidiaries.
2023-03-03 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.